secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001193125-26-002368
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics PALSONIFY Q4 net revenue >$5M; atumelnant Phase 2 CAH shows 67% A4 reduction
--------------------------------------------------------------------------------

- Unaudited Q4 2025 PALSONIFY net product revenue exceeded $5.0M, with >200 enrollment forms and >125 unique prescribers.
- Atumelnant 80mg in CAH cohort 4: 67% mean reduction in androstenedione, 88% of patients achieved physiologic glucocorticoid doses.
- No serious adverse events or hepatic transaminase AEs in cohort 4 or open-label extension (25 patients, >750 weeks cumulative exposure).
- About half of new PALSONIFY bottles reimbursed without Quickstart bridge; 12-month prior authorizations typical.
- Crinetics hosts investor call today 8:30 AM ET to discuss results and outlook.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312526002368/0001193125-26-002368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312526002368/d86003d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-002368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer